Cargando…
Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
INTRODUCTION: While the Dominantly Inherited Alzheimer Network Trials Unit (DIAN‐TU) was ongoing, external data suggested higher doses were needed to achieve targeted effects; therefore, doses of gantenerumab were increased 5‐fold, and solanezumab was increased 4‐fold. We evaluated to what extent mi...
Autores principales: | Wang, Guoqiao, Li, Yan, Xiong, Chengjie, McDade, Eric, Clifford, David B., Mills, Susan L., Santacruz, Anna M., Aschenbrenner, Andrew J., Hassenstab, Jason, Benzinger, Tammie L.S., Gordon, Brian A., Fagan, Anne M., Coalier, Kelley A., Libre‐Guerra, Jorge J., McCullough, Austin, Joseph‐Mathurin, Nelly, Chen, Charles D., Mummery, Catherine, Wendelberger, Barbara A., Gauthier, Serge, Masellis, Mario, Holdridge, Karen C., Yaari, Roy, Chatterjee, Saptarshi, Sims, John, Delmar, Paul, Kerchner, Geoffrey A., Bittner, Tobias, Hofmann, Carsten, Bateman, Randall J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632865/ https://www.ncbi.nlm.nih.gov/pubmed/36348972 http://dx.doi.org/10.1002/dad2.12367 |
Ejemplares similares
-
Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
por: Joseph‐Mathurin, Nelly, et al.
Publicado: (2022) -
Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023) -
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
por: Klein, Gregory, et al.
Publicado: (2019) -
Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
por: Willis, Brian A., et al.
Publicado: (2018) -
Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2019)